Stéphanie Dulucq, Françoise Rigal-Huguet, Franck E Nicolini, Pascale Cony-Makhoul, Martine Escoffre-Barbe, Martine Gardembas, Laurence Legros, Philippe Rousselot, Jixing Liu, Delphine Rea, Véronique De Mas, Sandrine Hayette, Sophie Raynaud, Caroline Lacoste-Roussillon, Fanny Robbesyn, Emilie Klein, Stéphane Morisset, François-Xavier Mahon, Gabriel Etienne
Molecular recurrence (MRec) occurs in about half of all patients with chronic myeloid leukaemia (CML) who discontinue tyrosine kinase inhibitors (TKI) in sustained deep molecular response. A second TKI discontinuation has been attempted in some patients who regain the discontinuation criteria after resuming treatment. Nilotinib treatment affords faster and deeper molecular responses than imatinib as first-line therapy. We prospectively evaluated the efficacy and safety of nilotinib (300 mg twice daily) in chronic-phase CML patients who experienced MRec, after imatinib discontinuation and analysed the probability of TFR after a new attempt in patients treated for 2 years with sustained MR4...
April 2, 2023: British Journal of Haematology